1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program

BACKGROUND: Cefiderocol (CFDC) has been developed for the treatment of serious infections caused by drug-resistant aerobic Gram-negative pathogens, including carbapenem-resistant (CR) Pseudomonas aeruginosa (CRPA). The current CFDC susceptibility breakpoints for P. aeruginosa differ between US Food...

Descripción completa

Detalles Bibliográficos
Autores principales: Satlin, Michael J, Fam, David, Echols, Roger, Longshaw, Christopher, Takemura, Miki, Yamano, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644515/
http://dx.doi.org/10.1093/ofid/ofab466.1448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644515/
http://dx.doi.org/10.1093/ofid/ofab466.1448

Ejemplares similares